1185019-85-5

Basic information

• Product Name: 3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)aniline
• Synonyms: 3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)aniline;EOS-60432
• CAS NO: 1185019-85-5
• Molecular Formula: C₁₀H₁₂N₄O
• Molecular Weight: 204.22848
• Mol File: 1185019-85-5.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 442.4±55.0 °C(Predicted)
• Appearance: /
• Density: 1.29±0.1 g/cm3(Predicted)
• PKA: 2.61±0.50(Predicted)
• CAS DataBase Reference: 3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)aniline(1185019-85-5)
• EPA Substance Registry System: 3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)aniline(1185019-85-5)

Safety Data

• Hazardous Substances Data: 1185019-85-5(Hazardous Substances Data)

Usage

Molecular weight

204.23 g/mol

Use

Intermediate in the synthesis of pharmaceuticals and agrochemicals

Physical properties

White to off-white crystalline solid with a melting point of 176-178°C

Application

Building block in the production of dyes, pigments, and other organic compounds

Safety

Handle with care and follow proper safety protocols when working with it.

Upstream product

• 97-52-9 2-methoxy-4-nitrophenylamine 
• 454-16-0 1-fluoro-2-methoxy-4-nitrobenzene 
• 1009-36-5 2-chloro-5-nitroanisole 
• 1185019-82-2 1-(2-methoxy-4-nitrophenyl)-3-methyl-1H-1,2,4-triazole 

Downstream Products

• 1263865-62-8 7-(4-fluorophenyl)-N²-(3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-N⁴-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine 
• 1314874-09-3 C₂₁H₂₇F₃N₈O 
• 1314874-08-2 C₂₁H₂₇F₃N₈O 
• 1314874-07-1 N-[3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-1-(1-methylethyl)-5-[3-(trifluoromethyl)-1-piperidinyl]-1H-1,2,4-triazol-3-amine 
• 1314873-79-4 C₂₁H₂₂ClN₇O₂ 

Relevant articles and documents

DNA-Model-Based Design and Execution of Some Fused Benzodiazepine Hybrid Payloads for Antibody-Drug Conjugate Modality

A new series with the tetrahydroisoquinoline-fused benzodiazepine (TBD) ring system combined with the surrogates of (1-methyl-1H-pyrrol-3-yl)benzene ( MPB ) payloads were designed and executed for conjugation with a monoclonal antibody for anticancer therapeutics. DNA models helped in rationally identifying modifications of the MPB binding component and guided structure-activity relationship generation. This hybrid series of payloads exhibited excellent in vitro activity when tested against a panel of various cancer cell lines. One of the payloads was appended with a lysosome-cleavable peptide linker and conjugated with an anti-mesothelin antibody via a site-specific conjugation method mediated by the enzyme bacterial transglutaminase (BTGase). Antibody-drug conjugate (ADC) 50 demonstrated good plasma stability and lysosomal cleavage. A single intravenous dose of ADC 50 (5 or 10 nmol/kg) showed robust efficacy in an N87 gastric cancer xenograft model.

ANTIPROLIFERATIVE COMPOUNDS AND CONJUGATES MADE THEREFROM

A compound capable of inhibiting cell proliferation, having a structure according to formula (I) wherein the variables in formula (I) are as defined in the specification. Such compounds are useful as anti-cancer agents, especially in antibody-drug conjugates.

FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF

The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.